Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
Alicia T. Widge(National Institute of Allergy and Infectious Diseases), Nadine Rouphael(Emory University), Lisa A. Jackson(Kaiser Permanente Washington Health Research Institute), Evan J. Anderson(Emory University), Paul C. Roberts(ActionAid), Mamodikoe Makhene(ActionAid), James D. Chappell(Vanderbilt University Medical Center), Mark R. Denison(Vanderbilt University Medical Center), Laura J. Stevens(Vanderbilt University Medical Center), Andrea J. Pruijssers(Vanderbilt University Medical Center), Adrian B. McDermott(ActionAid), Britta Flach(ActionAid), Bob C. Lin(ActionAid), Nicole A. Doria‐Rose(ActionAid), Sijy O’Dell(ActionAid), Stephen D. Schmidt(ActionAid), Kathleen M. Neuzil(University of Maryland, Baltimore), Hamilton Bennett(Moderna Therapeutics (United States)), Brett Leav(Moderna Therapeutics (United States)), Mat Makowski(Emmes (United States)), Jim Albert(Emmes (United States)), Kaitlyn Cross(Emmes (United States)), Venkata Viswanadh Edara(Emory University), Katharine Floyd(Emory University), Mehul S. Suthar(Emory University), Wendy Buchanan(ActionAid), Catherine J. Luke(ActionAid), Julie E. Ledgerwood(ActionAid), John R. Mascola(ActionAid), Barney S. Graham(ActionAid), John H. Beigel(ActionAid)
Cited by 827Open Access
Abstract
Immunogenicity and the mRNA-1273 SARS-CoV-2 Vaccine Thirty-four adults received two 100-μg injections of the mRNA-1273 SARS-CoV-2 vaccine, and serum anti–spike protein and neutralizing antibody tit...
Related Papers
No related papers found
Powered by citation graph analysis